Full Text of PDF (742k)
Article in Japanese
Abstract
Case Report
A case of small-cell lung cancer with durvalumab-induced autoimmune encephalitis
Masashi Oniwaa Shunsuke Misonoa Kahoru Moritaa Mikiko Yoneb Kentaro Tanakac Hiroaki Momia
aDepartment of Respiratory Medicine, Kagoshima City Hospital
bDepartment of Respiratory Medicine, Sendai Medical Association Hospital
cDepartment of Pulmonary Medicine, Graduate School of Medical & Dental Sciences, Kagoshima University
ABSTRACT
A 72-year-old man with extensive-stage small-cell lung cancer was treated with carboplatin, etoposide, and durvalumab as first-line therapy. After one course of chemotherapy, dysarthria and discomfort in the left upper limb appeared. Following a detailed examination, the patient was diagnosed with autoimmune encephalitis caused by durvalumab. Discontinuation of durvalumab and administration of steroids and intravenous gamma globulin improved the patient’s symptoms rapidly. Although autoimmune encephalitis is an uncommon cause of immune-related adverse events, it should be treated promptly because a delay in diagnosis can lead to serious complications.
KEYWORDS
Durvalumab Small cell lung cancer Autoimmune encephalitis Limbic encephalitis Immune-related adverse event
Received 26 Aug 2024 ／ Accepted 15 Jan 2025
AJRS, 14(3): 113-117, 2025
Copyright © The Japanese Respiratory Society All Rights Reserved.